Safety and Efficacy Study of Remote Ischemic Conditioning Combined With Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion of Anterior Circulation

Sponsor
Yi Yang (Other)
Overall Status
Recruiting
CT.gov ID
NCT04977869
Collaborator
(none)
498
1
2
27
18.4

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the efficacy and safety of remote ischemic conditioning for patients of acute ischemic stroke who underwent endovascular thrombectomy due to large vessel occlusion of anterior circulation.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Remote ischemic conditioning
  • Procedure: Sham remote ischemic conditioning
N/A

Detailed Description

In this study, 498 cases of ischemic stroke who undergo endovascular thrombectomy within 24 hours from the onset are included in 10 centers in China according to the principle of random, and parallel control. The experimental group receive basic treatment and remote ischemic conditioning for 200mmHg, 2 times per day for 7 consecutive days. The control group receive basic treatment and remote ischemic conditioning control for 60mmHg, 2 times per day for 7 consecutive days. Two groups will be followed up for 90 days to evaluate the efficacy and safety of remote ischemic conditioning for patients of acute ischemic stroke who underwent endovascular thrombectomy due to large vessel occlusion of anterior circulation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
498 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Safety and Efficacy Study of Remote Ischemic Conditioning Combined With Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion of Anterior Circulation: A Multicenter, Randomized, Parallel-controlled Clinical Trial
Actual Study Start Date :
Jul 1, 2021
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Oct 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: RIC+Standard medical treatment

RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days after endovascular thrombectomy. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2018.

Procedure: Remote ischemic conditioning
Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.

Placebo Comparator: Sham RIC+Standard medical treatment

Sham RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days after endovascular thrombectomy. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2018.

Procedure: Sham remote ischemic conditioning
Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.

Outcome Measures

Primary Outcome Measures

  1. Proportion of patients with modified Rankin Scale (mRS) Score 0-2 [3 months]

    Proportion of patients with modified Rankin Scale (mRS) Score 0-2. Ranged from 0 to 6, a low value represents a better outcome.

Secondary Outcome Measures

  1. National Institute of Health stroke scale (NIHSS) at 24 hours, 7 days, 30±3 days, 90±3 days after EVT. [24 hours, 7 days, 30±3 days, 90±3 days]

    National Institute of Health stroke scale (NIHSS) at 24 hours, 7 days, 30±3 days, 90±3 days after EVT. Ranged from 0 to 42, a low value represents a better outcome.

  2. Barthel Index (BI) at 24 hours, 7 days, 30±3 days, 90±3 days after EVT. [24 hours, 7 days, 30±3 days, 90±3 days]

    Barthel Index (BI) at 24 hours, 7 days, 30±3 days, 90±3 days after EVT. Ranged from 0 to 100, a high value represents a better outcome.

  3. modified Rankin Scale (mRS) at 24 hours, 7 days, 30±3 days, 90±3 days after EVT. [24 hours, 7 days, 30±3 days, 90±3 days]

    modified Rankin Scale (mRS) at 24 hours, 7 days, 30±3 days, 90±3 days after EVT. Ranged from 0 to 6, a low value represents a better outcome.

  4. The expanded Thrombolysis In Cerebral Infarction (eTICI) scale immediately after EVT [immediately after EVT]

    eTICI grade 0 is equivalent to no reperfusion or 0% filling of the downstream territory; eTICI 1 reflects thrombus reduction without any reperfusion of distal arteries; eTICI 2a is reperfusion in less than half or 1-49% of the territory; eTICI 2b50 is 50-66% reperfusion, exceeding the modified TICI (mTICI) 2B threshold but below the original TICI 2B cut-off point; eTICI 2b67 is 67-89% reperfusion, exceeding TICI but below TICI 2C; eTICI 2c is equivalent to TICI 2C or 90-99% reperfusion; and eTICI 3 is complete or 100% reperfusion, tantamount to TICI 3.

  5. Vascular recanalization rate 24 hours after EVT [24 hours,]

    Vascular recanalization rate 24 hours after EVT

  6. Frequency of Hemorrhagic transformation during hospitalization [7 days]

    Frequency of Hemorrhagic transformation during hospitalization

  7. Frequency of adverse events during follow-up [90 days]

    Severe adverse events through day-90 after the onset of acute ischemic stroke.

Other Outcome Measures

  1. Numeric rating scales (NRS) score during intervention [7 days]

    Numeric rating scales (NRS) score during intervention. Ranged from 0 to 10, a low value represents a less pain.

  2. The number of early withdrawal for safety or tolerability reasons [7 days]

    The number of early withdrawal for safety or tolerability reasons

  3. Blood pressure at 24 hours, 7 days, 30±3 days, 90±3 days after EVT. [24 hours, 7 days, 30±3 days, 90±3 days]

    Blood pressure at 24 hours, 7 days, 30±3 days, 90±3 days after EVT.

  4. Heart rate at 24 hours, 7 days, 30±3 days, 90±3 days after EVT. [24 hours, 7 days, 30±3 days, 90±3 days]

    Heart rate at 24 hours, 7 days, 30±3 days, 90±3 days after EVT.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
    1. Age ≥ 18 years, male or female
    1. Diagnosis of acute ischemic stroke due to large vessel occlusion of anterior circulation (large artery occlusion confirmed by head CTA or DSA) and history of emergent endovascular thrombectomy
    1. Baseline NIHSS ≥ 6
    1. Premorbid mRS ≤ 2
    1. Written informed consent obtained from the patient or legally responsible person
Exclusion Criteria:
    1. Contraindication of endovascular thrombectomy
    1. Contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture, or vascular injury in the upper limb, acute or subacute venous thrombosis, arterial occlusive disease, and subclavian steal syndrome
    1. Head CT showing cerebral hernia and midline displacement
    1. Pregnancy or lactation
    1. Previous remote ischemic conditioning therapy or similar treatment
    1. Severe hepatic and renal dysfunction
    1. Life expectancy of less than 3 months or inability to complete the study for other reasons
    1. Unwilling to be followed up or poor compliance
    1. Current or past participation in other clinical research, or participation in this study within 3 months prior to admission
    1. Other conditions that the researchers think make the patient unsuitable for the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 The First Hospital of Jilin University Changchun Jilin China 130000

Sponsors and Collaborators

  • Yi Yang

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yi Yang, Associated Dean of First Hospital of Jilin University, The First Hospital of Jilin University
ClinicalTrials.gov Identifier:
NCT04977869
Other Study ID Numbers:
  • SERIC-EVT
First Posted:
Jul 27, 2021
Last Update Posted:
Jul 22, 2022
Last Verified:
Jul 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 22, 2022